<DOC>
	<DOCNO>NCT00774748</DOCNO>
	<brief_summary>The purpose study ascertain whether subcutaneous port effective reliable way administer low molecular weight heparin ( LMWH ) enoxaparin patient prevention treatment venous thromboembolism .</brief_summary>
	<brief_title>Once Weekly Subcutaneous Ports Administration Anticoagulants</brief_title>
	<detailed_description>Subcutaneous port recently use administer Low Molecular Weight Heparin ( LMWH ) patient prevention treatment venous thromboembolism ; however , study perform evaluate port ' reliability deliver type drug . Hence , know whether absorption drug constant seven-day lifespan port . Although use subcutaneous port currently standard care , health care provider frequently use alternative method direct injection LMWH , particularly pediatric patient . The main advantage subcutaneous port decrease number needle stick use port administer medication . However , possible , due potential repeat bleed subcutaneous space port site factor , drug absorption may decrease seven day lifespan port , result decrease plasma drug level . Subtherapeutic LMWH level , hence , ineffective anticoagulation may result . This study 's aim determine current use subcutaneous port safe , effective reliable way administer LMWH purpose anticoagulation .</detailed_description>
	<mesh_term>Thromboembolism</mesh_term>
	<mesh_term>Venous Thromboembolism</mesh_term>
	<mesh_term>Anticoagulants</mesh_term>
	<criteria>Subjects receive twice daily dose therapeutic dos subcutaneous Enoxaparin . Subject dose Enoxaparin least one week . Anticipated length Enoxaparin treatment least 4 week . Age â‰¥ 18 year . Subject demonstration proper subcutaneous catheter care one education session investigator . Chronic renal insufficiency glomerular filtration rate &lt; 30 mL/min . Pregnancy Venous thromboembolism within last 4 week .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2012</verification_date>
	<keyword>low molecular weight heparin</keyword>
	<keyword>enoxaparin</keyword>
	<keyword>Lovenox</keyword>
	<keyword>Insuflon</keyword>
	<keyword>subcutaneous catheter</keyword>
	<keyword>twice daily dose subcutaneous enoxaparin</keyword>
</DOC>